TVTX Travere Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TVTX

Price (delayed)

$46.185

Market cap

$4.29B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.22

Enterprise value

$4.54B

?
Relative Growth: Rel. Growth: 82
Relative Strength: Rel. Strength: 93
Relative Valuation: Rel. Valuation: 12
Relative Profitability: Rel. Profitability: 47

Travere Therapeutics is a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this ...

Highlights
Travere Therapeutics's gross profit has surged by 101% YoY and by 10% QoQ
The revenue has surged by 96% year-on-year and by 9% since the previous quarter
TVTX's equity is down by 14% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www..travere.com
Peers: OPK ORGO

Key stats

What are the main financial stats of TVTX

TVTX stock price

How has the Travere Therapeutics stock price performed over time
Intraday
2.18%
1 week
-3.3%
1 month
2.84%
1 year
203.45%
YTD
20.87%
QTD
55.45%

Financial performance

How have Travere Therapeutics's revenue and profit performed over time
Revenue
$536.2M
Gross profit
$528.59M
Operating income
-$57.06M
Net income
-$21.42M
Gross margin
98.6%
Net margin
-4%
Travere Therapeutics's gross profit has surged by 101% YoY and by 10% QoQ
The revenue has surged by 96% year-on-year and by 9% since the previous quarter
The net margin has soared by 95% year-on-year and by 23% since the previous quarter
TVTX's net income has surged by 91% year-on-year and by 16% since the previous quarter

Price vs fundamentals

How does TVTX's price correlate with its fundamentals

Growth

What is Travere Therapeutics's growth rate over time

Valuation

What is Travere Therapeutics stock price valuation
P/E
N/A
P/B
43.15
P/S
7.91
EV/EBIT
N/A
EV/EBITDA
72.41
EV/Sales
8.47
The company's EPS has surged by 92% YoY and by 24% QoQ
The price to book (P/B) is 130% higher than the 5-year quarterly average of 18.4 and 33% higher than the last 4 quarters average of 31.7
TVTX's equity is down by 14% since the previous quarter
The revenue has surged by 96% year-on-year and by 9% since the previous quarter
The stock's P/S is 49% above its last 4 quarters average of 5.2

Efficiency

How efficient is Travere Therapeutics business performance
The company's return on sales has surged by 98% YoY and by 32% QoQ
Travere Therapeutics's return on equity has surged by 98% YoY and by 33% QoQ
The return on invested capital has surged by 94% year-on-year and by 21% since the previous quarter
The company's return on assets has surged by 91% YoY and by 16% QoQ

Dividends

What is TVTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TVTX.

Financial health

How did Travere Therapeutics financials performed over time
TVTX's total assets is 22% more than its total liabilities
The company's current ratio has surged by 53% YoY and by 14% QoQ
The quick ratio has increased by 44% YoY and by 12% from the previous quarter
Travere Therapeutics's debt to equity has plunged by 73% YoY but it has increased by 16% from the previous quarter
The debt has declined by 18% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.